A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

Overview of attention for article published in Journal of Translational Medicine, February 2005

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 2 news outlets
twitter: 4 X users

patent: 8 patents
facebook: 1 Facebook page

Readers on

mendeley: 496 Mendeley
connotea: 1 Connotea

Summary News X Patents Facebook

So far, Altmetric has seen 2 news stories from 2 outlets.

Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre - Press Release

Digital Journal, 25 Jan 2016

OCEANSIDE, CA--(Marketwired - January 25, 2016) - Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today…

Therapeutics Solutions Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From

Biospace, 25 Jan 2016

) - Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an exclusive intellectual…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.